Phathom Capex To Depreciation vs Ev To Sales Analysis

PHAT Stock

USD 13.25 0.21 1.61%

Phathom Pharmaceuticals financial indicator trend analysis is much more than just breaking down Phathom Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Phathom Pharmaceuticals is a good investment. Please check the relationship between Phathom Pharmaceuticals Capex To Depreciation and its Ev To Sales accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phathom Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.

Capex To Depreciation vs Ev To Sales

Capex To Depreciation vs Ev To Sales Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Phathom Pharmaceuticals Capex To Depreciation account and Ev To Sales. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Phathom Pharmaceuticals' Capex To Depreciation and Ev To Sales is 0.49. Overlapping area represents the amount of variation of Capex To Depreciation that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of Phathom Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Phathom Pharmaceuticals' Capex To Depreciation and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Depreciation of Phathom Pharmaceuticals are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Capex To Depreciation i.e., Phathom Pharmaceuticals' Capex To Depreciation and Ev To Sales go up and down completely randomly.

Correlation Coefficient

0.49

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most indicators from Phathom Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Phathom Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phathom Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.Selling General Administrative is likely to gain to about 305.2 M in 2025, whereas Issuance Of Capital Stock is likely to drop slightly above 91.5 M in 2025.

	2022	2023	2024	2025 (projected)
Interest Expense	27.3M	42.0M	72.0M	75.6M
Depreciation And Amortization	620K	575K	795K	635.5K

Interest Expense Depreciation And Amortization

Phathom Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Other Liab	Property Plant And Equipment Net	Other Assets	Long Term Debt
Total Assets		0.65	0.69	0.79	-0.19	0.09	0.88	-0.14	-0.87	0.85	1.0	1.0	0.94	0.93	0.87	0.96	0.8	0.39	0.92	1.0	0.99	0.51	0.8	0.76	0.58	0.8
Short Long Term Debt Total	0.65		0.94	0.92	-0.75	-0.37	0.72	0.65	-0.89	0.53	0.6	0.6	0.75	0.59	0.62	0.71	0.93	-0.29	0.52	0.64	0.6	0.93	0.68	0.44	0.25	0.82
Other Current Liab	0.69	0.94		0.98	-0.56	-0.15	0.81	0.52	-0.86	0.7	0.66	0.66	0.77	0.67	0.61	0.75	0.86	-0.08	0.61	0.69	0.63	0.95	0.67	0.55	0.53	0.75
Total Current Liabilities	0.79	0.92	0.98		-0.57	-0.19	0.86	0.4	-0.91	0.8	0.76	0.76	0.84	0.73	0.64	0.82	0.91	-0.05	0.66	0.79	0.74	0.9	0.74	0.67	0.6	0.81
Total Stockholder Equity	-0.19	-0.75	-0.56	-0.57		0.88	-0.35	-0.81	0.6	-0.19	-0.12	-0.12	-0.41	-0.12	-0.12	-0.31	-0.73	0.82	-0.03	-0.17	-0.12	-0.65	-0.49	-0.2	0.15	-0.66
Net Tangible Assets	0.09	-0.37	-0.15	-0.19	0.88		-0.1	-0.6	0.3	0.0	0.14	0.14	-0.15	0.13	0.21	-0.04	-0.44	0.89	0.21	0.11	0.15	-0.24	-0.32	-0.12	0.32	-0.43
Current Deferred Revenue	0.88	0.72	0.81	0.86	-0.35	-0.1		0.06	-0.92	0.9	0.87	0.87	0.94	0.93	0.68	0.94	0.83	0.22	0.88	0.88	0.85	0.6	0.93	0.89	0.63	0.84
Net Debt	-0.14	0.65	0.52	0.4	-0.81	-0.6	0.06		-0.29	-0.16	-0.21	-0.21	0.07	-0.16	-0.04	-0.02	0.42	-0.79	-0.23	-0.15	-0.21	0.7	0.12	-0.22	-0.29	0.32
Retained Earnings	-0.87	-0.89	-0.86	-0.91	0.6	0.3	-0.92	-0.29		-0.78	-0.84	-0.84	-0.95	-0.85	-0.76	-0.93	-0.97	0.03	-0.8	-0.87	-0.84	-0.73	-0.9	-0.75	-0.41	-0.94
Accounts Payable	0.85	0.53	0.7	0.8	-0.19	0.0	0.9	-0.16	-0.78		0.86	0.86	0.84	0.85	0.57	0.85	0.69	0.31	0.81	0.85	0.81	0.49	0.78	0.92	0.86	0.7
Cash	1.0	0.6	0.66	0.76	-0.12	0.14	0.87	-0.21	-0.84	0.86		1.0	0.92	0.94	0.86	0.95	0.76	0.45	0.93	1.0	1.0	0.46	0.77	0.79	0.61	0.76
Cash And Short Term Investments	1.0	0.6	0.66	0.76	-0.12	0.14	0.87	-0.21	-0.84	0.86	1.0		0.92	0.94	0.86	0.95	0.76	0.45	0.93	1.0	1.0	0.46	0.77	0.79	0.61	0.76
Common Stock Shares Outstanding	0.94	0.75	0.77	0.84	-0.41	-0.15	0.94	0.07	-0.95	0.84	0.92	0.92		0.94	0.81	0.99	0.88	0.17	0.91	0.94	0.91	0.59	0.94	0.77	0.49	0.94
Capital Surpluse	0.93	0.59	0.67	0.73	-0.12	0.13	0.93	-0.16	-0.85	0.85	0.94	0.94	0.94		0.84	0.97	0.71	0.45	0.99	0.94	0.93	0.43	0.88	0.81	0.58	0.78
Other Current Assets	0.87	0.62	0.61	0.64	-0.12	0.21	0.68	-0.04	-0.76	0.57	0.86	0.86	0.81	0.84		0.86	0.68	0.39	0.87	0.88	0.88	0.47	0.62	0.48	0.31	0.68
Other Stockholder Equity	0.96	0.71	0.75	0.82	-0.31	-0.04	0.94	-0.02	-0.93	0.85	0.95	0.95	0.99	0.97	0.86		0.84	0.28	0.95	0.96	0.94	0.54	0.91	0.8	0.53	0.89
Total Liab	0.8	0.93	0.86	0.91	-0.73	-0.44	0.83	0.42	-0.97	0.69	0.76	0.76	0.88	0.71	0.68	0.84		-0.21	0.64	0.79	0.75	0.79	0.81	0.65	0.33	0.91
Net Invested Capital	0.39	-0.29	-0.08	-0.05	0.82	0.89	0.22	-0.79	0.03	0.31	0.45	0.45	0.17	0.45	0.39	0.28	-0.21		0.52	0.4	0.45	-0.28	0.04	0.27	0.47	-0.15
Short Long Term Debt	0.92	0.52	0.61	0.66	-0.03	0.21	0.88	-0.23	-0.8	0.81	0.93	0.93	0.91	0.99	0.87	0.95	0.64	0.52		0.93	0.92	0.37	0.83	0.75	0.56	0.74
Total Current Assets	1.0	0.64	0.69	0.79	-0.17	0.11	0.88	-0.15	-0.87	0.85	1.0	1.0	0.94	0.94	0.88	0.96	0.79	0.4	0.93		0.99	0.51	0.79	0.76	0.59	0.79
Net Working Capital	0.99	0.6	0.63	0.74	-0.12	0.15	0.85	-0.21	-0.84	0.81	1.0	1.0	0.91	0.93	0.88	0.94	0.75	0.45	0.92	0.99		0.44	0.76	0.75	0.55	0.75
Short Term Debt	0.51	0.93	0.95	0.9	-0.65	-0.24	0.6	0.7	-0.73	0.49	0.46	0.46	0.59	0.43	0.47	0.54	0.79	-0.28	0.37	0.51	0.44		0.47	0.31	0.38	0.64
Other Liab	0.8	0.68	0.67	0.74	-0.49	-0.32	0.93	0.12	-0.9	0.78	0.77	0.77	0.94	0.88	0.62	0.91	0.81	0.04	0.83	0.79	0.76	0.47		0.79	0.38	0.93
Property Plant And Equipment Net	0.76	0.44	0.55	0.67	-0.2	-0.12	0.89	-0.22	-0.75	0.92	0.79	0.79	0.77	0.81	0.48	0.8	0.65	0.27	0.75	0.76	0.75	0.31	0.79		0.71	0.63
Other Assets	0.58	0.25	0.53	0.6	0.15	0.32	0.63	-0.29	-0.41	0.86	0.61	0.61	0.49	0.58	0.31	0.53	0.33	0.47	0.56	0.59	0.55	0.38	0.38	0.71		0.28
Long Term Debt	0.8	0.82	0.75	0.81	-0.66	-0.43	0.84	0.32	-0.94	0.7	0.76	0.76	0.94	0.78	0.68	0.89	0.91	-0.15	0.74	0.79	0.75	0.64	0.93	0.63	0.28

Click cells to compare fundamentals

Phathom Pharmaceuticals Account Relationship Matchups

Phathom Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	295.1M	189.4M	164.8M	413.8M	378.3M	267.1M
Short Long Term Debt Total	49.0M	91.3M	97.1M	139.0M	554.9M	582.7M
Other Current Liab	30.4M	12.8M	14.8M	7.1M	54.9M	57.7M
Total Current Liabilities	55.5M	18.9M	26.2M	38.8M	85.7M	90.0M
Total Stockholder Equity	194.3M	72.2M	(74.8M)	(72.8M)	(253.6M)	(240.9M)
Net Tangible Assets	228.0M	194.3M	72.2M	(74.8M)	(67.3M)	(64.0M)
Net Debt	(238.5M)	(91.9M)	(58.3M)	(242.4M)	257.7M	270.6M
Retained Earnings	(385.5M)	(529.4M)	(727.1M)	(928.7M)	(1.3B)	(1.2B)
Accounts Payable	16.8M	5.2M	10.0M	12.6M	10.5M	8.8M
Cash	287.5M	183.3M	155.4M	381.4M	297.3M	243.5M
Non Current Assets Total	3.7M	2.9M	4.3M	16.4M	18.2M	19.1M
Non Currrent Assets Other	384K	341K	299K	9.9M	13.2M	13.9M
Cash And Short Term Investments	287.5M	183.3M	155.4M	381.4M	297.3M	243.5M
Common Stock Shares Outstanding	33.2M	37.0M	39.1M	51.3M	63.2M	40.4M
Liabilities And Stockholders Equity	295.1M	189.4M	164.8M	413.8M	378.3M	267.1M
Non Current Liabilities Total	45.3M	98.4M	213.4M	447.8M	546.2M	573.5M
Other Current Assets	7.7M	6.5M	10.3M	13.2M	20.9M	12.9M
Other Stockholder Equity	579.8M	601.5M	652.3M	855.9M	1.0B	657.4M
Total Liab	100.8M	117.3M	239.6M	486.6M	631.9M	663.5M
Net Invested Capital	241.3M	161.8M	20.5M	65.1M	(52.2M)	(49.6M)
Total Current Assets	291.4M	186.5M	160.5M	397.4M	360.1M	259.7M
Net Working Capital	235.8M	167.6M	134.3M	358.7M	274.4M	223.4M
Short Term Debt	8.3M	974K	1.4M	726K	20.3M	21.3M
Property Plant And Equipment Net	3.4M	2.6M	3.5M	3.6M	2.1M	3.0M
Long Term Debt	39.6M	89.7M	95.3M	137.8M	201.4M	107.5M
Capital Lease Obligations	2.0M	1.7M	1.8M	1.2M	501K	476.0K
Property Plant And Equipment Gross	3.4M	2.6M	5.0M	5.7M	4.9M	4.2M
Non Current Liabilities Other	4.1M	8.7M	117.0M	309.5M	344.8M	362.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC